Document Detail


Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
MedLine Citation:
PMID:  21165537     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RESULTS: Mean SUVmax in tumours of all examinations was 2.2 (stdev: 0.4, min: 1.3, max: 3.4) after 2 h and 2.4 (stdev: 0.7, min: 1.1, max: 4.4) after 4 h. In the neck musculature the mean SUVmax was 1.5 at both time points and the mean SUVmean decreased from 1.2 after 2 h to 1.1 after 4 h, respectively. These effects resulted in significantly rising contrast ratios from MISO2 to MISO4. The differently defined contrasts revealed significantly higher values for examinations 4 h p.i. (p < 0.002).
CONCLUSION: Data acquisition of [¹⁸F]FMISO should be done 4 h p.i. to gather the optimal contrast, preferably allowing further analysis, e. g. hypoxic sub volume definition for therapy planning.
Authors:
N Abolmaali; R Haase; A Koch; D Zips; J Steinbach; M Baumann; J Kotzerke; K Zöphel
Related Documents :
15738037 - Posterior sacculation of the uterus in a patient presenting with flank pain at 29 weeks...
20452417 - Use of magnetic resonance imaging (mri) and micro-computed tomography (micro-ct) in the...
16049997 - Meconium peritonitis: prenatal diagnosis, postnatal management and outcome.
16012307 - Fast fetal magnetic resonance imaging.
14712127 - Comparison of axial high-resolution ct and thin-section multiplanar reformation (mpr) f...
20861377 - Time-dependent effects of corticosteroids on human amygdala processing.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-17
Journal Detail:
Title:  Nuklearmedizin. Nuclear medicine     Volume:  50     ISSN:  0029-5566     ISO Abbreviation:  Nuklearmedizin     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-21     Completed Date:  2011-04-12     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7609387     Medline TA:  Nuklearmedizin     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  22-7     Citation Subset:  IM    
Affiliation:
OncoRay-Molecular and Biological Imaging, National Center for Radiation Research in Oncology, Institut und Poliklinik für Radiologische Diagnostik, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Nasreddin.Abolmaali@tu-dresden.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Small Cell / radionuclide imaging*
Female
Head and Neck Neoplasms / radionuclide imaging*
Humans
Image Enhancement / methods*
Male
Middle Aged
Misonidazole / administration & dosage,  analogs & derivatives*,  diagnostic use
Positron-Emission Tomography / methods*
Radiopharmaceuticals / administration & dosage,  diagnostic use
Reproducibility of Results
Sensitivity and Specificity
Time Factors
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 13551-87-6/Misonidazole; 13551-89-8/fluoromisonidazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FDG PET/CT in cancer therapy monitoring. Computer-assisted analysis of baseline together with up to ...
Next Document:  Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the ...